We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured
Published in Oncology

Journal Scan / Research · May 06, 2021

Two Doses of the COVID-19 Vaccine BNT162b2 Are Required for Patients With Cancer

The Lancet Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Safety and Immunogenicity of One Versus Two Doses of the COVID-19 Vaccine BNT162b2 for Patients With Cancer: Interim Analysis of a Prospective Observational Study
Lancet Oncol 2021 Apr 27;[EPub Ahead of Print], L Monin, AG Laing, M Muñoz-Ruiz, DR McKenzie, I Del Molino Del Barrio, T Alaguthurai, C Domingo-Vila, TS Hayday, C Graham, J Seow, S Abdul-Jawad, S Kamdar, E Harvey-Jones, R Graham, J Cooper, M Khan, J Vidler, H Kakkassery, S Sinha, R Davis, L Dupont, I Francos Quijorna, C O'Brien-Gore, PL Lee, J Eum, M Conde Poole, M Joseph, D Davies, Y Wu, A Swampillai, BV North, A Montes, M Harries, A Rigg, J Spicer, MH Malim, P Fields, P Patten, F Di Rosa, S Papa, T Tree, KJ Doores, AC Hayday, S Irshad

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading